Vanderbilt-Ingram Cancer Center Lebanon has moved to a new location that provides better convenience, more space for patients and continued excellence in care.
Clinicians have begun seeing patients at 1616 West Main St., Suite 101, in Lebanon. A multidisciplinary team offers cancer patients medical oncology, surgical oncology consultations, infusion services, palliative care and pain management. Plans are in place to add gynecological oncology services later this year. The Cancer Center relocated from its prior space inside Vanderbilt Wilson County Hospital due to patient demand four years after its opening. Radiation oncology services will continue to be provided at the hospital campus.
“Ever since opening in the hospital space four years ago, we’ve seen exponential growth in our services there, and we’ve been able to bring additional specialty care,” said Waleed Khalaf, MD, PhD, medical director for Regional Network Cancer Care at Vanderbilt-Ingram. “We’ve been well received by the community, and we need a bigger space.”
The larger space features an on-site infusion pharmacy and eight private spaces for infusion therapy. It has state-of-the art medical equipment and new furnishings. The Cancer Center is in the same space as Vanderbilt Integrated Primary Care.
Appointments can be scheduled from 8 a.m. to 5 p.m., Monday through Friday. Call 615-936-8422 and request the Wilson County location to schedule.
“We’ve brought the same quality of care locally that we offer at the Vanderbilt University Medical Center campus,” Khalaf said. “There is very little that we are not able to offer that we offer in Nashville.”
The Lebanon and Mt. Juliet Chambers of Commerce will be hosting a ribbon cutting/open house at the Cancer Center on Monday, Feb. 3 from 1-2 p.m.
A Comprehensive Cancer Center designated by the National Cancer Institute, Vanderbilt-Ingram offers treatment options unique to the region provided by internationally renowned physicians. Vanderbilt-Ingram has helped launch treatments through clinical trials that have become new standards for cancer care, including targeted therapies and immunotherapies.
